Blocking effects of siRNA on VEGF expression in human colorectal cancer cells

Table 1 Expression of VEGF and its receptors FLT-1 and FLK-1 in CRC and normal mucosa n (%)

	n	VEGF		FLT-1		FLK-1
		Negative	Positive	Negative	Positive	Negative	Positive
Normal mucosa	14	10	4 (28.6)	9	5 (35.7)	10	4 (28.6)
CRC	82	25	57 (69.5)b	14	68 (82.9)b	15	67 (81.7)b

^bP < 0.01 vs normal mucosa. VEGF: Vascular endothelial cell growth factor; FLT-1: Fms-like tyrosine kinase 1; FLK-1: Fetal liver kinase 1; CRC: Colorectal carcinoma.

Table 2 Relationship between VEGF expression and its receptors FLT-1 and FLK-1 and clinical pathological features of CRC n (%)

	n	VEGF		FLT-1		FLK-1
		Negative	Positive	Negative	Positive	Negative	Positive
Age (yr)
< 60	41	14	27 (65.9)	10	31 (75.6)	9	32 (78.0)
≥ 60	41	11	30 (73.2)	4	37 (90.2)	6	35 (85.4)
Gender
Male	49	13	36 (73.5)	11	38 (77.6)	10	39 (79.6)
Female	33	12	21 (63.6)	3	30 (90.9)	5	28 (84.8)
Depth of tumor invasion
Not exceed muscular layer	25	10	15 (60.0)	5	20 (80.0)	5	20 (80.0)
Exceed muscular layer	57	15	42 (73.7)	9	48 (84.2)	10	47 (82.5)
Lymph node metastasis
Negative	52	21	31 (59.6)	8	44 (84.6)	8	44 (84.6)
Positive	30	4	26 (86.7)b	6	24 (80.0)	7	23 (76.7)
Degree of differentiation
Well	20	10	10 (50.0)	4	16 (80.0)	5	15 (75.0)
Moderate	41	10	31 (75.6)	5	36 (87.8)	5	36 (87.8)
Poor	21	5	16 (76.2)	5	16 (76.2)	5	16 (76.2)
Duke’s stage
A	19	8	11 (57.9)a	4	15 (78.9)	4	15 (78.9)
B	33	13	20 (60.6)	4	29 (87.9)	4	29 (87.9)
C + D	30	4	26 (86.7)	6	24 (80.0)	7	23 (86.7)

^aP < 0.05 vs stage B and C + D groups;

^bP < 0.01 vs the lymph node-negative group.